Very recently, a study evaluating the tumor samples from patients with advanced HCC showed that, among 28 patients treated with anti-PD-1 in the frontline, responders had upregulated IFNγ signaling and MHC II-related antigen presentation [84]. Here, PDCD1 is linked to hepatocellular carcinoma.